Kevin Balthaser, Chief Financial Officer at Aclaris Therapeutics, Inc. (ACRS), bought 9,490 shares at $7.90 ($75K) on 2023-09-06, disclosed to the SEC on 2023-09-07.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.